SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
BOSTON, Jan. 27, 2016 -- Topokine Therapeutics, the biotechnology company pioneering topical medications to contour the face and body, announced today that it has initiated a Phase 2 study of TAT4 Gel for reduction of nasolabial folds. Commonly known as laugh lines, nasolabial folds are a common sign of aging. They are typically treated with injectable dermal fillers.
TAT4 Gel is the second product in Topokine’s innovative pipeline of topical adipomodulatory medicines. Applied to the skin once daily, TAT4 acts pharmacologically to increase subcutaneous fat, thereby softening skin wrinkles and folds. As part of the randomized, placebo-controlled trial, patients are applying TAT4 Gel to their nasolabial folds for three months.
“Our faces lose volume as we age, which deepens nasolabial folds,” said Jody Levine, MD, FAAD, FAAP, a New York dermatologist recognized by New Beauty as one of the nation’s Top Beauty Doctors. “TAT4 was designed to enhance tissue volume by increasing subcutaneous fat.”
“Today, many patients and dermatologists rely on injectable dermal fillers to rejuvenate the skin,” said Michael Singer, MD, PhD, Topokine’s Chief Scientific Officer. “TAT4 is based on a simple concept—that instead of injecting foreign substances into the skin, a topical product can signal the patient’s own cells to reestablish a more youthful contour.”
About Topokine
Topokine is a clinical-stage biotechnology company developing topical prescription medications that act pharmacologically on adipocytes to contour the face and body. The company’s lead program, XAF5 Ointment, is in late-stage clinical development for reduction of undereye bags (steatoblepharon). Topokine’s pipeline also includes TAT4 Gel, which increases subcutaneous fat and is in Phase 2 development as a “topical filler” for reduction of laugh lines (nasolabial folds). The company’s assets are protected by over 75 issued and pending patents worldwide. For more information, visit www.topokine.com.
Contact: Matt Burke [email protected]
